Back to top

TransMedics Group: Robust Transplant Demand Supports Buy Rating Despite Price Target Cut to $106

Analyst Michael Matson from Needham maintained a Buy rating on TransMedics Group and decreased the price target to $106.00 from $142.00. Michael Ma...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

TransMedics Group, Inc. (TMDX)